Gemtuzumab ozogamicin - Pfizer

Drug Profile

Gemtuzumab ozogamicin - Pfizer

Alternative Names: Anti-CD33-monoclonal-antibody-calicheamicin; Anti-CD33-monoclonal-antibody-p67-6-calicheamicin-conjugate; CDP-771; CMA-676; Gemtuzumab; HP67-6-N-acetyl-gamma-dimethyl-acbut; Human-anti-CD33-monoclonal-antibody-P67-6-calicheamicin-conjugate; Mylotarg; WAY-CMA-676

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Developer Pfizer
  • Class Aminoglycosides; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Apr 2018 Registered for Acute myeloid leukaemia (Combination therapy, First-line therapy, In adolescents, In adults) in European Union, Iceland, Norway and Liechtenstein (IV)
  • 22 Feb 2018 The EMA's Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion for gemtuzumab ozogamicin for the treatment of Acute myeloid leukaemia (First-line therapy, Combination therapy, In adolescents, In adults)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top